^
    Back
    Association details:
    Biomarker:CXCR4 overexpression
    Cancer:Triple Negative Breast Cancer
    Drug Class:EGFR-targeted antibody-drug conjugate
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    NPJ Breast Cancer
    Title:

    Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

    Published date:
    09/17/2021
    Excerpt:
    Six patients experienced a rapid fatal recurrence (RR) and other 6 had later non-fatal recurrences (LR)...RR cases showed high expression of SOX2 and CXCR4. Our results indicate that high expression of cell cycle genes, combined with cold immunological phenotype, may predict strong TNBC resistance to NAT and rapid progression after it.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1038/s41523-021-00334-5